Financial Architects Inc Increases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Financial Architects Inc increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,822 shares of the company’s stock after acquiring an additional 260 shares during the period. Johnson & Johnson comprises 1.2% of Financial Architects Inc’s investment portfolio, making the stock its 19th biggest position. Financial Architects Inc’s holdings in Johnson & Johnson were worth $8,372,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bluesphere Advisors LLC lifted its holdings in shares of Johnson & Johnson by 2.3% in the first quarter. Bluesphere Advisors LLC now owns 2,593 shares of the company’s stock valued at $426,000 after buying an additional 59 shares during the period. BFT Financial Group LLC boosted its holdings in Johnson & Johnson by 1.2% in the second quarter. BFT Financial Group LLC now owns 5,170 shares of the company’s stock worth $852,000 after purchasing an additional 59 shares in the last quarter. Davis Rea LTD. grew its stake in Johnson & Johnson by 2.3% in the 2nd quarter. Davis Rea LTD. now owns 2,666 shares of the company’s stock valued at $439,000 after buying an additional 60 shares during the last quarter. White Lighthouse Investment Management Inc. raised its stake in Johnson & Johnson by 0.7% during the 2nd quarter. White Lighthouse Investment Management Inc. now owns 8,691 shares of the company’s stock valued at $1,432,000 after purchasing an additional 60 shares during the last quarter. Finally, Dumont & Blake Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 0.3% in the 2nd quarter. Dumont & Blake Investment Advisors LLC now owns 19,337 shares of the company’s stock worth $3,186,000 after acquiring an additional 61 shares during the period. 67.29% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson stock traded up $0.40 during midday trading on Wednesday, hitting $165.20. 138,592 shares of the stock were exchanged, compared to its average volume of 7,095,660. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $434.89 billion, a price-to-earnings ratio of 24.78, a price-to-earnings-growth ratio of 2.23 and a beta of 0.71. Johnson & Johnson has a 52-week low of $133.65 and a 52-week high of $179.92. The business’s 50-day moving average price is $172.45 and its 200-day moving average price is $167.19.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 20th. The company reported $2.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.29 by $0.19. The business had revenue of $23.31 billion for the quarter, compared to analysts’ expectations of $22.54 billion. Johnson & Johnson had a return on equity of 37.06% and a net margin of 19.92%. The firm’s quarterly revenue was up 27.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.67 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 9.65 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Investors of record on Tuesday, August 24th were paid a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date of this dividend was Monday, August 23rd. Johnson & Johnson’s dividend payout ratio is currently 52.80%.

Several brokerages have recently issued reports on JNJ. SVB Leerink reissued a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, July 29th. Credit Suisse Group set a $193.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, June 7th. Finally, Morgan Stanley cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective for the company. in a report on Tuesday, September 7th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Buy” and a consensus price target of $190.38.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading: Put Option

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.